Verve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.
Verve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.